 Nichole Carlson
Concepts (510)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bayes Theorem | 6 | 2020 | 327 | 1.320 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 169 | 1.110 |
Why?
| | Models, Statistical | 6 | 2020 | 595 | 1.050 |
Why?
| | Hydrocortisone | 6 | 2015 | 267 | 0.950 |
Why?
| | Hormones | 3 | 2017 | 132 | 0.850 |
Why?
| | Emphysema | 1 | 2023 | 106 | 0.810 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 164 | 0.760 |
Why?
| | Outpatients | 6 | 2023 | 325 | 0.720 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 267 | 0.710 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 318 | 0.700 |
Why?
| | Diabetes Complications | 1 | 2022 | 208 | 0.690 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2019 | 57 | 0.630 |
Why?
| | Metadata | 1 | 2018 | 7 | 0.630 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 150 | 0.620 |
Why?
| | Computer Simulation | 4 | 2017 | 873 | 0.600 |
Why?
| | State Health Plans | 2 | 2008 | 32 | 0.590 |
Why?
| | Models, Biological | 3 | 2017 | 1611 | 0.580 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 216 | 0.570 |
Why?
| | Ovary | 3 | 2017 | 190 | 0.560 |
Why?
| | Residence Characteristics | 6 | 2010 | 274 | 0.530 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 128 | 0.530 |
Why?
| | Genome | 1 | 2018 | 269 | 0.530 |
Why?
| | Reproduction | 1 | 2017 | 176 | 0.530 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2272 | 0.510 |
Why?
| | Child Health Services | 2 | 2008 | 175 | 0.500 |
Why?
| | Software | 2 | 2019 | 526 | 0.500 |
Why?
| | Obesity | 12 | 2023 | 2505 | 0.490 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 17 | 0.480 |
Why?
| | Computational Biology | 1 | 2018 | 528 | 0.480 |
Why?
| | Brain Injuries | 5 | 2010 | 459 | 0.460 |
Why?
| | Biometry | 2 | 2017 | 62 | 0.460 |
Why?
| | Health Services for the Aged | 2 | 2019 | 70 | 0.460 |
Why?
| | Circadian Rhythm | 4 | 2013 | 356 | 0.460 |
Why?
| | Health Services Accessibility | 4 | 2010 | 756 | 0.450 |
Why?
| | Humans | 87 | 2023 | 114045 | 0.440 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 26 | 0.430 |
Why?
| | Pulsatile Flow | 1 | 2013 | 54 | 0.430 |
Why?
| | Environment Design | 3 | 2010 | 24 | 0.420 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 49 | 0.410 |
Why?
| | Female | 67 | 2023 | 59324 | 0.390 |
Why?
| | Specimen Handling | 1 | 2013 | 153 | 0.390 |
Why?
| | Adult | 47 | 2023 | 30375 | 0.380 |
Why?
| | Saliva | 1 | 2013 | 188 | 0.380 |
Why?
| | Walking | 4 | 2010 | 422 | 0.380 |
Why?
| | Alzheimer Disease | 4 | 2023 | 442 | 0.380 |
Why?
| | Gonadotropins | 3 | 2023 | 37 | 0.370 |
Why?
| | Parkinson Disease | 4 | 2009 | 345 | 0.360 |
Why?
| | White Matter | 2 | 2023 | 105 | 0.360 |
Why?
| | Aged | 24 | 2023 | 18969 | 0.350 |
Why?
| | Levodopa | 2 | 2007 | 23 | 0.340 |
Why?
| | Activities of Daily Living | 3 | 2010 | 348 | 0.340 |
Why?
| | Hypogonadism | 2 | 2015 | 75 | 0.340 |
Why?
| | Oregon | 8 | 2011 | 65 | 0.340 |
Why?
| | Endocrine System | 1 | 2009 | 19 | 0.320 |
Why?
| | Testosterone | 2 | 2010 | 341 | 0.320 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2087 | 0.310 |
Why?
| | Estradiol | 6 | 2023 | 450 | 0.310 |
Why?
| | Prenatal Care | 1 | 2010 | 250 | 0.300 |
Why?
| | Technology | 1 | 2009 | 78 | 0.300 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 47 | 0.290 |
Why?
| | Levonorgestrel | 4 | 2011 | 31 | 0.290 |
Why?
| | Health Behavior | 3 | 2010 | 701 | 0.290 |
Why?
| | Cognition Disorders | 3 | 2008 | 476 | 0.290 |
Why?
| | Young Adult | 14 | 2022 | 10444 | 0.280 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.280 |
Why?
| | Perception | 2 | 2007 | 309 | 0.280 |
Why?
| | Male | 39 | 2022 | 55396 | 0.280 |
Why?
| | Middle Aged | 32 | 2021 | 26605 | 0.280 |
Why?
| | Methylphenidate | 1 | 2007 | 36 | 0.270 |
Why?
| | Aged, 80 and over | 11 | 2021 | 6306 | 0.270 |
Why?
| | Smoking Cessation | 1 | 2010 | 374 | 0.270 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 54 | 0.270 |
Why?
| | Time Factors | 13 | 2017 | 6077 | 0.260 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2384 | 0.260 |
Why?
| | Antibodies, Viral | 4 | 2023 | 520 | 0.260 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3254 | 0.260 |
Why?
| | Poverty | 2 | 2010 | 440 | 0.250 |
Why?
| | Healthcare Disparities | 1 | 2010 | 479 | 0.240 |
Why?
| | Cluster Analysis | 2 | 2023 | 452 | 0.240 |
Why?
| | Gliosis | 2 | 2023 | 27 | 0.240 |
Why?
| | Lung | 3 | 2023 | 3521 | 0.230 |
Why?
| | Medicaid | 1 | 2008 | 404 | 0.220 |
Why?
| | Body Mass Index | 6 | 2019 | 1957 | 0.220 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1080 | 0.210 |
Why?
| | Oocytes | 2 | 2020 | 169 | 0.210 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 4402 | 0.210 |
Why?
| | Prospective Studies | 9 | 2023 | 6195 | 0.210 |
Why?
| | Aging | 4 | 2008 | 1611 | 0.200 |
Why?
| | Hospitalization | 6 | 2022 | 1762 | 0.200 |
Why?
| | Benchmarking | 1 | 2023 | 161 | 0.200 |
Why?
| | Markov Chains | 3 | 2017 | 114 | 0.190 |
Why?
| | Monte Carlo Method | 3 | 2017 | 136 | 0.190 |
Why?
| | Disability Evaluation | 4 | 2018 | 271 | 0.190 |
Why?
| | Weight Gain | 2 | 2022 | 453 | 0.180 |
Why?
| | Healthy Aging | 1 | 2021 | 18 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.180 |
Why?
| | Doxycycline | 2 | 2011 | 54 | 0.180 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 79 | 0.180 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 17 | 0.180 |
Why?
| | Oocyte Donation | 1 | 2020 | 4 | 0.180 |
Why?
| | Memory, Episodic | 1 | 2021 | 38 | 0.180 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 4 | 0.180 |
Why?
| | Prescription Drugs | 1 | 2022 | 116 | 0.170 |
Why?
| | Sarcoidosis | 1 | 2022 | 133 | 0.170 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 32 | 0.170 |
Why?
| | Quality of Life | 5 | 2018 | 2343 | 0.170 |
Why?
| | Apomorphine | 3 | 2009 | 5 | 0.170 |
Why?
| | Menstruation | 2 | 1991 | 35 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 180 | 0.170 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 49 | 0.170 |
Why?
| | Internet | 2 | 2018 | 591 | 0.170 |
Why?
| | Fractals | 1 | 2019 | 6 | 0.170 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 20 | 0.170 |
Why?
| | Radial Nerve | 1 | 1999 | 9 | 0.170 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 24 | 0.160 |
Why?
| | Human Growth Hormone | 2 | 2014 | 38 | 0.160 |
Why?
| | Astrocytes | 1 | 2021 | 159 | 0.160 |
Why?
| | Health Status | 3 | 2010 | 716 | 0.160 |
Why?
| | Spirometry | 1 | 2019 | 223 | 0.160 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1078 | 0.160 |
Why?
| | Vital Capacity | 1 | 2019 | 254 | 0.160 |
Why?
| | Hip Fractures | 1 | 2019 | 75 | 0.150 |
Why?
| | Risk Factors | 9 | 2022 | 8614 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2018 | 98 | 0.150 |
Why?
| | Bibliometrics | 1 | 2018 | 43 | 0.150 |
Why?
| | Contraception | 2 | 1991 | 117 | 0.150 |
Why?
| | Regression Analysis | 2 | 2019 | 945 | 0.150 |
Why?
| | Sheep, Domestic | 1 | 2017 | 33 | 0.150 |
Why?
| | Algorithms | 3 | 2017 | 1469 | 0.150 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 522 | 0.150 |
Why?
| | Pregnancy | 8 | 2023 | 5499 | 0.140 |
Why?
| | Eligibility Determination | 2 | 2008 | 59 | 0.140 |
Why?
| | Rhinitis | 2 | 2010 | 128 | 0.140 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 1 | 0.140 |
Why?
| | Premature Birth | 1 | 2020 | 275 | 0.140 |
Why?
| | Psychomotor Performance | 3 | 2009 | 281 | 0.140 |
Why?
| | Lactation | 1 | 2018 | 149 | 0.140 |
Why?
| | Adolescent | 13 | 2020 | 17800 | 0.140 |
Why?
| | Double-Blind Method | 7 | 2011 | 1656 | 0.140 |
Why?
| | Medically Uninsured | 2 | 2008 | 122 | 0.140 |
Why?
| | Affect | 3 | 2008 | 246 | 0.140 |
Why?
| | Metabolic Diseases | 1 | 2018 | 98 | 0.140 |
Why?
| | Cohort Studies | 5 | 2010 | 4883 | 0.140 |
Why?
| | Family Planning Services | 2 | 2008 | 68 | 0.140 |
Why?
| | Sinusitis | 2 | 2010 | 174 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2017 | 2764 | 0.140 |
Why?
| | Retrospective Studies | 10 | 2023 | 12521 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 94 | 0.140 |
Why?
| | Endoscopy | 2 | 2010 | 245 | 0.140 |
Why?
| | Hypothyroidism | 2 | 2007 | 65 | 0.140 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 222 | 0.130 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 141 | 0.130 |
Why?
| | Low Back Pain | 1 | 2018 | 93 | 0.130 |
Why?
| | Antibodies | 1 | 2018 | 365 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2018 | 313 | 0.130 |
Why?
| | Dietary Fats | 1 | 2018 | 287 | 0.130 |
Why?
| | Models, Animal | 1 | 2017 | 340 | 0.130 |
Why?
| | Brain | 5 | 2023 | 2355 | 0.130 |
Why?
| | Personnel Selection | 1 | 2016 | 62 | 0.130 |
Why?
| | Recovery of Function | 2 | 2010 | 573 | 0.130 |
Why?
| | Cross-Over Studies | 5 | 2009 | 439 | 0.130 |
Why?
| | Otolaryngology | 1 | 2016 | 69 | 0.120 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 180 | 0.120 |
Why?
| | Patient Dropouts | 1 | 2015 | 66 | 0.120 |
Why?
| | Biomarkers | 4 | 2021 | 3397 | 0.120 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 102 | 0.120 |
Why?
| | Breast Feeding | 1 | 2018 | 366 | 0.120 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 130 | 0.120 |
Why?
| | Dementia | 2 | 2008 | 186 | 0.120 |
Why?
| | Menstrual Cycle | 3 | 2011 | 108 | 0.120 |
Why?
| | Acromegaly | 1 | 2014 | 12 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 175 | 0.120 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 122 | 0.120 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 189 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2017 | 297 | 0.110 |
Why?
| | Analysis of Variance | 5 | 2009 | 1218 | 0.110 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 714 | 0.110 |
Why?
| | Health Care Costs | 1 | 2017 | 381 | 0.110 |
Why?
| | Interviews as Topic | 3 | 2010 | 575 | 0.110 |
Why?
| | Antibody Formation | 2 | 2022 | 266 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1002 | 0.110 |
Why?
| | Secretory Rate | 1 | 2013 | 16 | 0.110 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 282 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 150 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 366 | 0.100 |
Why?
| | Severity of Illness Index | 5 | 2022 | 2537 | 0.100 |
Why?
| | Electronics | 1 | 2013 | 66 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 192 | 0.100 |
Why?
| | Age Factors | 8 | 2018 | 2885 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 187 | 0.100 |
Why?
| | Medical Records | 1 | 2013 | 153 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4392 | 0.100 |
Why?
| | Insulin | 1 | 2022 | 2080 | 0.100 |
Why?
| | Antibodies, Monoclonal | 3 | 2022 | 1257 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 477 | 0.100 |
Why?
| | Cognition | 3 | 2008 | 990 | 0.100 |
Why?
| | Memory | 3 | 2008 | 209 | 0.100 |
Why?
| | Wakefulness | 1 | 2013 | 128 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2015 | 459 | 0.100 |
Why?
| | Urban Health | 2 | 2009 | 73 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 371 | 0.100 |
Why?
| | Risk Assessment | 2 | 2017 | 2958 | 0.090 |
Why?
| | Statistics as Topic | 2 | 2009 | 291 | 0.090 |
Why?
| | Progestins | 1 | 2011 | 75 | 0.090 |
Why?
| | Cytokines | 2 | 2015 | 1824 | 0.090 |
Why?
| | Amenorrhea | 1 | 2011 | 26 | 0.090 |
Why?
| | Equipment Design | 1 | 2013 | 503 | 0.090 |
Why?
| | Dopamine Agonists | 2 | 2008 | 32 | 0.090 |
Why?
| | Diet | 1 | 2018 | 1080 | 0.090 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 23 | 0.090 |
Why?
| | Automobile Driving | 2 | 2010 | 129 | 0.090 |
Why?
| | Birth Certificates | 1 | 2010 | 8 | 0.090 |
Why?
| | United States | 6 | 2020 | 12137 | 0.090 |
Why?
| | Estrone | 1 | 2010 | 35 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2017 | 932 | 0.090 |
Why?
| | Birth Rate | 2 | 2020 | 19 | 0.090 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 39 | 0.090 |
Why?
| | Live Birth | 2 | 2020 | 47 | 0.090 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 13 | 0.090 |
Why?
| | Pregnancy Rate | 2 | 2020 | 54 | 0.090 |
Why?
| | Geographic Information Systems | 2 | 2010 | 37 | 0.090 |
Why?
| | Sex Factors | 5 | 2018 | 1706 | 0.090 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 71 | 0.090 |
Why?
| | Thyroxine | 2 | 2007 | 57 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1764 | 0.090 |
Why?
| | Abortion, Induced | 2 | 2008 | 71 | 0.090 |
Why?
| | Cities | 1 | 2010 | 80 | 0.080 |
Why?
| | Treatment Outcome | 7 | 2015 | 9049 | 0.080 |
Why?
| | Personality | 1 | 2011 | 112 | 0.080 |
Why?
| | Exercise | 3 | 2010 | 1642 | 0.080 |
Why?
| | Child, Preschool | 4 | 2018 | 9114 | 0.080 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 8 | 0.080 |
Why?
| | Mortality | 1 | 2011 | 283 | 0.080 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 32 | 0.080 |
Why?
| | Independent Living | 1 | 2010 | 84 | 0.080 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 67 | 0.080 |
Why?
| | Telecommunications | 1 | 2009 | 16 | 0.080 |
Why?
| | Progesterone | 3 | 2015 | 232 | 0.080 |
Why?
| | Postmenopause | 1 | 2010 | 301 | 0.080 |
Why?
| | Rural Health | 1 | 2009 | 67 | 0.080 |
Why?
| | Drug Interactions | 2 | 2007 | 337 | 0.080 |
Why?
| | Logistic Models | 2 | 2010 | 1829 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2371 | 0.080 |
Why?
| | Foot | 1 | 2009 | 103 | 0.080 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 81 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 135 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 23 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 33 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 18 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 11 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 27 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 22 | 0.070 |
Why?
| | Counseling | 1 | 2010 | 342 | 0.070 |
Why?
| | Population Surveillance | 1 | 2010 | 385 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 256 | 0.070 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 28 | 0.070 |
Why?
| | Internship and Residency | 1 | 2016 | 920 | 0.070 |
Why?
| | Atrophy | 1 | 2007 | 152 | 0.070 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 11 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 111 | 0.070 |
Why?
| | Time Perception | 1 | 2007 | 24 | 0.070 |
Why?
| | Awareness | 1 | 2007 | 93 | 0.070 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 119 | 0.070 |
Why?
| | Infant | 3 | 2010 | 7943 | 0.070 |
Why?
| | Antigens, Viral | 1 | 2007 | 176 | 0.070 |
Why?
| | Movement | 1 | 2009 | 242 | 0.070 |
Why?
| | Albumins | 1 | 2007 | 89 | 0.070 |
Why?
| | Suicide, Attempted | 1 | 2009 | 316 | 0.070 |
Why?
| | Tremor | 1 | 2007 | 45 | 0.070 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 193 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1815 | 0.070 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 106 | 0.070 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 544 | 0.060 |
Why?
| | Animals | 6 | 2023 | 31565 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 7 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 330 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1690 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 398 | 0.060 |
Why?
| | Health Policy | 1 | 2008 | 330 | 0.060 |
Why?
| | Administration, Oral | 1 | 2007 | 725 | 0.060 |
Why?
| | Child | 5 | 2018 | 18401 | 0.060 |
Why?
| | Health Promotion | 1 | 2010 | 675 | 0.060 |
Why?
| | Neurologic Examination | 2 | 2008 | 113 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2008 | 434 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 524 | 0.060 |
Why?
| | Family | 1 | 2008 | 589 | 0.060 |
Why?
| | Likelihood Functions | 2 | 2017 | 126 | 0.060 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 11 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 768 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 43 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2007 | 636 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 474 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 63 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 83 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 635 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1175 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 180 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 375 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2007 | 762 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3039 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 71 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1471 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 11 | 0.050 |
Why?
| | Physical Examination | 2 | 2018 | 221 | 0.050 |
Why?
| | Acids | 1 | 2002 | 16 | 0.050 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 117 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 951 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 675 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 61 | 0.050 |
Why?
| | Breast Neoplasms | 2 | 2011 | 1846 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 124 | 0.050 |
Why?
| | Neuroimaging | 1 | 2023 | 249 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 90 | 0.050 |
Why?
| | Puberty | 1 | 2002 | 135 | 0.050 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 157 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2022 | 166 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 210 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 11 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 245 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 14 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 242 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 44 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 29 | 0.040 |
Why?
| | Case-Control Studies | 4 | 2009 | 3003 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 77 | 0.040 |
Why?
| | Depression | 1 | 2008 | 1133 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 115 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 1836 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1168 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 211 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 92 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1791 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 82 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 301 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 766 | 0.040 |
Why?
| | Denmark | 1 | 2017 | 39 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2314 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2000 | 330 | 0.040 |
Why?
| | Electromyography | 1 | 1999 | 326 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 381 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2023 | 642 | 0.040 |
Why?
| | Neoplasms | 1 | 2011 | 2086 | 0.040 |
Why?
| | Confidence Intervals | 2 | 2008 | 302 | 0.040 |
Why?
| | Viruses | 1 | 2018 | 94 | 0.040 |
Why?
| | Psychological Tests | 1 | 2018 | 120 | 0.040 |
Why?
| | Milk | 1 | 2018 | 123 | 0.040 |
Why?
| | Biostatistics | 1 | 2017 | 15 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 56 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 100 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 225 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 813 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 441 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 286 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1206 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 723 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 787 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 209 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 182 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 55 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1331 | 0.030 |
Why?
| | Systole | 1 | 2015 | 176 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 771 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1128 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 104 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 224 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 4680 | 0.030 |
Why?
| | Risk | 1 | 2017 | 810 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3498 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 608 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 2784 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 545 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 492 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 194 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 160 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 100 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 618 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 368 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4090 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2008 | 926 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 813 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 312 | 0.030 |
Why?
| | Fatty Acids | 1 | 2015 | 380 | 0.030 |
Why?
| | Follicular Phase | 2 | 2004 | 36 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 572 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 453 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 650 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 287 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 3315 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1422 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 799 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5038 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 22 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 46 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 49 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 108 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 500 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 959 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 670 | 0.020 |
Why?
| | Amides | 1 | 2010 | 87 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 151 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 146 | 0.020 |
Why?
| | Income | 1 | 2010 | 167 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 739 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 345 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 83 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 151 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 16 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 10 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 163 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 28 | 0.020 |
Why?
| | Employment | 1 | 2010 | 137 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 761 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 33 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 259 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 410 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 11 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 12 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 4595 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 181 | 0.020 |
Why?
| | Parity | 1 | 1988 | 97 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 57 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 7 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 362 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 20 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 61 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 26 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 25 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 408 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 39 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 141 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 438 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 132 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 84 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 56 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 137 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 41 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 42 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 426 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 80 | 0.020 |
Why?
| | Research | 1 | 2010 | 389 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 203 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 53 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 139 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 85 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 82 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 444 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 571 | 0.020 |
Why?
| | Safety | 1 | 2008 | 298 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 82 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 481 | 0.020 |
Why?
| | Mental Recall | 1 | 2007 | 171 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 286 | 0.020 |
Why?
| | Virus Diseases | 1 | 2007 | 195 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 378 | 0.020 |
Why?
| | Dopamine Agents | 1 | 2005 | 14 | 0.020 |
Why?
| | Length of Stay | 1 | 2009 | 957 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1447 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 594 | 0.020 |
Why?
| | Vestibular Diseases | 1 | 2005 | 22 | 0.020 |
Why?
| | Self Efficacy | 1 | 2008 | 353 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 55 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 70 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 41 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 227 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 919 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1577 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 473 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 76 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 49 | 0.010 |
Why?
| | Skin | 1 | 2007 | 653 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 713 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 292 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 944 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1204 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 151 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 235 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 1958 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 25 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 32 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 22 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 169 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 33 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 47 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 87 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 87 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 427 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 587 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2453 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 147 | 0.010 |
Why?
| | Periodicity | 1 | 2000 | 54 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 273 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 41 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 337 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 2 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 22 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 441 | 0.010 |
Why?
| | Vaccination | 1 | 2007 | 1202 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1052 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2090 | 0.010 |
Why?
| | Fever | 1 | 2000 | 280 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 631 | 0.010 |
Why?
| | Mice | 1 | 2007 | 14843 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|